TMS for PTSD in Youth
The purpose of this study is to test whether transcranial magnetic stimulation, or TMS, is an acceptable and helpful treatment for ongoing symptoms of posttraumatic stress syndrome disorder (PTSD) in 12-20 year olds. Ongoing PTSD refers to symptoms that continue after completing trauma-focused psychotherapy. About 1 in
| Condition(s) | Post Traumatic Stress Disorder (PTSD) |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The purpose of this study is to test whether transcranial magnetic stimulation, or TMS, is an acceptable and helpful treatment for ongoing symptoms of posttraumatic stress syndrome disorder (PTSD) in 12-20 year olds. Ongoing PTSD refers to symptoms that continue after completing trauma-focused psychotherapy. About 1 in 4 patients need additional help to overcome PTSD after completing psychotherapy. Currently, scientists do not know the best way to help adolescents with persistent PTSD, and this study will test TMS as a possible treatment, and hopefully lead to future studies including more people. |
| Who can participate | Inclusion Criteria: 1. Males and females; Age 12-20 2. Have previously completed at least 9 sessions of trauma-focused therapy in our clinical trial or in the community 3. Have current self-reported symptom score of 20 or greater on the UCLA PTSD Reaction index 4. Willing to attend 10 TMS treatment sessions within a 30-day period 5. Fluent in English Exclusion Criteria: 1. History of seizures 2. History of head injury with loss of consciousness and concussive sequelae 3. Brain abnormality such as tumor or other observable abnormality 4. Currently receiving psychotherapy or TMS treatment 5. Currently pregnant 6. MRI contraindications (metal in body, orthodontic braces) 7. Diagnosis of bipolar 1 or a psychotic disorder |
| Ages | 12 Years to 20 Years |
| Sex | All |
| Lead sponsor | The University of Texas Health Science Center at San Antonio |
| Locations | San Antonio, Texas, United States |
| Start date | 2026-05-09 |
| NCT ID | NCT07401225 |
| Official listing | https://clinicaltrials.gov/study/NCT07401225 |